News
Invivyd, Inc. Reports Positive In Vitro Neutralization Data for PEMGARDA™ Against Dominant SARS-CoV-2 Variant LP.8.1 March 05, 2025 — 07:11 am EST Written by None for Quiver Quantitative -> ...
Invivyd, Inc., a biopharmaceutical company focused on developing treatments for serious viral infectious diseases, has announced a conference call on May 15, 2025, at 8:30 a.m. ET to discuss its ...
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2.
WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that it has formed a best-in-class clinical and translational study group, the SPEAR Study Group ...
Invivyd, Inc. (Nasdaq: IVVD), today announced the addition of Akiko Iwasaki, Ph.D., Professor of Immunobiology at Yale School of Medicine, to the SPEAR (Spike Protein Elimination and Recovery) Study ...
Invivyd, Inc. (NASDAQ:IVVD) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ETCompany ParticipantsKatie Falzone - VP, Corporate ControllerMarc Elia ...
On Wednesday, H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while maintaining a Buy rating. This revision follows a revenue ...
Invivyd, Inc. (NASDAQ:IVVD) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ETCorporate ParticipantsScott Young - SVP, Investor Relations and ...
LOS ANGELES, CA / ACCESSWIRE / March 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Invivyd, Inc. f/k/a Adagio ...
View the latest Invivyd Inc. (IVVD) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results